AveXis steps up gene therapy pursuit of Biogen's SMA pathfinder | Fierce Biotech
AveXis Presents Promising Trial Results of Gene Therapy for SMA Type 1
AveXis's House Of Cards: Dubious Trials, Drug Lawsuit And Fraud Allegations - Strong Sell With 94% Downside (NASDAQ:AVXS) | Seeking Alpha
AveXis Doubles Down, Adding 200 Jobs, $60M to Durham Gene Therapy Facility | North Carolina Biotechnology Center
The world's most expensive drug?
g944461.jpg
AveXis Gene Therapy Manufacturing Facility, North Carolina, USA
g925518.jpg
AveXis discloses data on AVXS-101 efficacy in treating early onset spinal muscular atrophy – TreatSMA
AveXis Inc.: Buy at the High? | The Motley Fool
With new AveXis name, Novartis spotlights marquee role for gene therapy business | Fierce Pharma
AveXis' Lone-Drug Bubble - Much Ado About Nothing? (NASDAQ:AVXS) | Seeking Alpha
AveXIS Announcement – Utah Program for Inherited Neuromuscular Disorders
AveXis's House Of Cards: Dubious Trials, Drug Lawsuit And Fraud Allegations - Strong Sell With 94% Downside (NASDAQ:AVXS) | Seeking Alpha
AveXis discloses data on AVXS-101 efficacy in treating early onset spinal muscular atrophy – TreatSMA
Promising results in phase 1 SMA gene therapy trial - Muscular Dystrophy Association
A 2nd Patient Death Reported in Novartis' Gene Therapy Trial | BioSpace
AveXis' Lone-Drug Bubble - Much Ado About Nothing? (NASDAQ:AVXS) | Seeking Alpha
Therapeutic approaches for spinal muscular atrophy (SMA) | Gene Therapy
AveXis chooses BIA Separations to support gene therapy pipeline
AveXis' Lone-Drug Bubble - Much Ado About Nothing? (NASDAQ:AVXS) | Seeking Alpha
Zolgensma® – TreatSMA
AveXis' Lone-Drug Bubble - Much Ado About Nothing? (NASDAQ:AVXS) | Seeking Alpha
FDA Accepts AveXis' BLA for SMA Drug Zolgensma Under Priority Review - Muscular Dystrophy Association
Novartis-bound AveXis posts early look at data from pivotal SMA gene therapy trial | Fierce Biotech
AveXis nabs breakthrough tag for gene therapy, plans pivotal trial start in 2017 | Fierce Biotech
